期刊文献+

加味藿香正气散联合西药治疗腹泻型肠易激综合征临床研究 被引量:8

Clinical Study of Jiawei Huoxiang Zhengqi Powder Combined with Western Medicine for Treatment of Diarrhea-predominant Irritable Bowel Syndrome
原文传递
导出
摘要 目的:观察加味藿香正气散联合匹维溴胺与黛立新治疗腹泻型肠易激综合征(IBS-D)的疗效。方法:将102例患者随机分为2组,对照组用匹维溴胺和黛立新治疗,治疗组用加味藿香正气散联合匹维溴胺与黛立新治疗,疗程4周,在治疗结束时记录患者症状改善等情况,根据症状评分综合分析2组的疗效。结果:2组患者在治疗后症状均有改善(P<0.01);但治疗组症状改善比对照组更明显(P<0.01);总有效率治疗组92.0%,对照组78.8%,2组比较,差异有非常显著性意义(P<0.01)。结论:加味藿香正气散联合匹维溴胺与黛立新治疗IBS-D有良好疗效,且无毒副反应。 Objective: To observe the therapeutic effects of Jiawei Huoxiang Zhengqi Powder combined with pinaverium bromide and flupentixol-melitracen for diarrhea-predominant irritable bowel syndrome(IBS-D). Methods: One hundred and two patients were randomly divided into control group and treatment group. The two groups were treated with pinaverium bromide and flupentixol-melitracen, and the treatment group received Jiawei Huoxiang Zhengqi Powder additionally. The treatment course lasted four weeks. After treatment, the relief of symptoms was observed, and the therapeutic effect of two groups was evaluated according to the scores of symptoms. Results: The symptoms were much relieved in both groups after treatment(P 〈 0.01 compared with those before treatment), the relief in the treatment group being superior to that in the control group(P 〈 0.01). The total effective rate was 92.0% in the treatment group and 78.8% in the control group, the difference being significant (P 〈 0.01). Conclusion: Jiawei Huoxiang Zhengqi Powder combined with pinaverium bromide and flupentixol-melitracen is effective and safe for treatment of IBS-D.
出处 《新中医》 CAS 北大核心 2011年第3期31-33,共3页 New Chinese Medicine
关键词 肠易激综合征 腹泻型 中西医结合疗法 藿香正气散 匹维溴胺 黛立新 Irritable Bowel Syndrome Diarrhea-predominant TCM-WM Therapy Huoxiang Zhengqi Powder Pinaverium Bromide Flupentixol-melitracen
  • 相关文献

参考文献3

二级参考文献15

  • 1Drossman DA.Psychosocial and psychophysiologic mechanisms in GI Ⅲ ness.In:Kirsner JB,ed.The growth of gastroenterologic knowledge in the 20th century.Philadelphia:Lea & Febiger; 1993.41~432.
  • 2Whitehead WE,Palsson O,Jones KR.Systematic review of the comorbidity of irritable bowel syndrome with other disorders:what are the causes and implications? Gastroenterology,2002,122:1140~1156.
  • 3Drossman DA,Camilleri M,Mayer EA,Whitehead WE.AGA technical review on irritable bowel syndrome.Gastroenterology,2002,123:2108~2131.
  • 4Lea R,Whorwell PJ.New insights into the psychosocial aspects of irritable bowel syndrome.Curr Gastroenterol Rep,2003,5:343~350.
  • 5Drossman DA.The functional gastrointestinal disorders and the Rome Ⅲ process.Gastroenterology,2006,130:1377~1390.
  • 6Longstreth GF,Thompson WG,Chey WD,Houghton LA,Mearin F,Spiller RC.Functional bowel disorder.Gastroenterology,2006,130:1480~1491.
  • 7O'Donnell LJ,Virjee J,Heaton KW.Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.BMJ,1990,300:439~440.
  • 8Longstreth GF,Drossman DA.Severe irritable bowel and functional abdominal pain syndromes:managing the patient and health care costs.Clin Gastroenterol Hepatol,2005,3:397~400.
  • 9Chey WD,Chey WY,Heath AT,Dukes GE,Carter EG,Northcutt A,Ameen VZ.Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.Am J Gastroenterol,2004,99:2195~2203.
  • 10Muller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Loffier H.Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.Aliment Pharmacol Ther,2005,21:11~20.

共引文献1587

同被引文献92

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部